Femcon Fe

GPTKB entity

Statements (49)
Predicate Object
gptkbp:instance_of gptkb:Planned_Parenthood
gptkbp:approves gptkb:FDA
gptkbp:brand gptkb:Femcon_Fe
gptkbp:category gptkb:X
gptkbp:class combination oral contraceptive
gptkbp:clinical_trial conducted for safety and efficacy
gptkbp:contraindication liver disease
certain cancers
history of blood clots
smoking over age 35
gptkbp:dosage_form chewable tablet
gptkbp:drug_interactions gptkb:St._John's_Wort
antibiotics
anticonvulsants
HIV medications
gptkbp:effective_date 2000-09-01
gptkbp:form gptkb:tablet
gptkbp:healthcare_provider_consultation recommended before use
https://www.w3.org/2000/01/rdf-schema#label Femcon Fe
gptkbp:indication pregnancy prevention
gptkbp:ingredients gptkb:norethindrone
gptkb:ethinyl_estradiol
gptkbp:is_effective_against over 99% with perfect use
91% with typical use
gptkbp:is_monitored_by blood pressure recommended
gptkbp:label gptkb:Teva_Pharmaceuticals_USA,_Inc.
gptkbp:manufacturer gptkb:Teva_Pharmaceuticals
gptkbp:market_position marketed
gptkbp:missed_dose_instructions take as soon as remembered
if missed for 2 days, use backup contraception
gptkbp:package_insert available online
gptkbp:packaging blister pack
gptkbp:patient_population provided with prescription
gptkbp:refills available
gptkbp:requires prescription only
gptkbp:route_of_administration oral
gptkbp:side_effect headache
nausea
weight gain
breast tenderness
mood changes
reported in clinical studies
gptkbp:storage room temperature
gptkbp:strength 0.4 mg norethindrone
35 mcg ethinyl estradiol
gptkbp:type_of_care important for effectiveness
gptkbp:withdrawal_bleeding may occur
gptkbp:bfsParent gptkb:ethinylestradiol
gptkbp:bfsLayer 7